会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • Methods of determining film thicknesses for an aerosol delivery article
    • 确定气溶胶输送制品的膜厚度的方法
    • US20050037506A1
    • 2005-02-17
    • US10912462
    • 2004-08-04
    • Ron HaleAmy LuDaniel MyersJoshua Rabinowitz
    • Ron HaleAmy LuDaniel MyersJoshua Rabinowitz
    • A61K9/00A61K31/00A61M15/00G01N1/18
    • A61K9/007A61K9/0073A61K31/00A61M11/001A61M15/0028A61M2205/3653A61M2209/02
    • Methods for determining the film thickness of a compound composition needed to provide a selected purity and yield of a condensation aerosol via vaporization of the compound composition have applications in aerosol delivery technology, in pulmonary drug delivery, and in other therapeutic treatment regimes. The methods for determining such film thickness, for use in a device having a film of drug composition to be aerosolized, include generating purities and yields of a drug composition by vaporizing films of the drug composition from substrates at two or more temperatures in the range of 150° C. to 500° C. and two or more film thickness in the range of 0.05 to 50 microns, determining from these yields and purities if a thickness and temperature exist where the aerosol has at least 90% purity and at least 50% yield, and repeated such measurements until the selected purity and yield requirement are met.
    • 用于确定通过化合物组合物蒸发提供选择的纯度和产生缩合气溶胶所需的化合物组合物的膜厚度的方法可用于气雾剂递送技术,肺部药物递送和其它治疗方案中。 用于确定具有待雾化的药物组合物的膜的装置中的这种膜厚度的方法包括通过在两个或多个温度范围内从基材中蒸发药物组合物的膜而产生药物组合物的纯度和产率 150℃至500℃,以及0.05至50微米范围内的两个或多个膜厚度,如果存在厚度和温度,则气溶胶具有至少90%的纯度和至少50%的纯度, 产量和重复这样的测量,直到满足所选择的纯度和产量要求。
    • 7. 发明申请
    • Diuretic Aerosols and Methods of Making and Using Them
    • 利尿剂及其使用方法
    • US20070140982A1
    • 2007-06-21
    • US11670892
    • 2007-02-02
    • Nathan EveryRon HaleAmy LuJoshua Rabinowitz
    • Nathan EveryRon HaleAmy LuJoshua Rabinowitz
    • A61K9/14
    • A61K9/0073A61K9/007A61K31/58
    • Described herein are diuretic condensation aerosols and methods of making and using them. Kits for delivering a condensation aerosol are also described. The diuretic aerosols typically comprise diuretic condensation aerosol particles that comprise a diuretic compound. In some variations the diuretic compound is selected from the group consisting of bumetanide, ethacrynic acid, furosemide, muzolimine, spironolactone, torsemide, triamterene, tripamide, BG 9928, and BG 9719. Methods of treating edema using the described aerosols are also provided. In general, the methods typically comprise the step of administering a therapeutically effective amount of diuretic condensation aerosol to a person with edema. The diuretic condensation aerosol may be administered in a single inhalation, or may be administered in more than one inhalation. Methods of forming a diuretic condensation aerosol are also described. The methods typically comprise the steps of providing a diuretic composition, vaporizing the composition to form a vapor, and then condensing the diuretic composition vapor.
    • 本文描述的是利尿凝结气溶胶及其制备和使用方法。 还描述了用于递送冷凝气雾剂的组件。 利尿剂气溶胶通常包含利尿剂缩合气溶胶颗粒,其包含利尿剂。 在一些变体中,利尿剂化合物选自布美他尼,依西醋酸,呋塞米,多佐立胺,螺内酯,托塞米明,扑热息痛,三酰胺,BG 9928和BG 9719.还提供了使用所述气溶胶治疗水肿的方法。 通常,所述方法通常包括向具有水肿的人施用治疗有效量的利尿冷凝气雾剂的步骤。 利尿冷凝气雾剂可以在单次吸入中施用,或者可以在多于一次的吸入中施用。 还描述了形成利尿冷凝气雾剂的方法。 所述方法通常包括提供利尿组合物,蒸发组合物以形成蒸气,然后冷凝利尿组合物蒸气的步骤。
    • 10. 发明申请
    • AEROSOL DELIVERY SYSTEM AND USES THEREOF
    • 航空运输系统及其用途
    • US20080038363A1
    • 2008-02-14
    • US11687466
    • 2007-03-16
    • Alejandro ZaffaroniJoshua Rabinowitz
    • Alejandro ZaffaroniJoshua Rabinowitz
    • A61K9/14A61K31/5513A61P25/00A61K31/5517
    • A61M11/041A61M11/001A61M11/005A61M11/042A61M11/048A61M15/002
    • A device, method, and system for producing a condensation aerosol are disclosed. The device includes a chamber having an upstream opening and a downstream opening which allow gas to flow through the chamber, and a heat-conductive substrate located at a position between the upstream and downstream openings. Formed on the substrate is a drug composition film containing a therapeutically effective dose of a drug when the drug is administered in aerosol form. A heat source in the device is operable to supply heat to the substrate to produce a substrate temperature greater than 300 oC, and to substantially volatilize the drug composition film from the substrate in a period of 2 seconds or less. The device produces an aerosol containing less than about 10% by weight drug composition degradation products and at least 50% of the drug composition of said film.
    • 公开了一种用于生产冷凝气雾剂的装置,方法和系统。 该装置包括具有允许气体流过腔室的上游开口和下游开口的腔室,以及位于上游和下游开口之间位置的导热基底。 在基质上形成药物组合物膜,当药物以气溶胶形式施用时,其含有治疗有效剂量的药物。 装置中的热源可操作以向基板供应热量以产生大于300℃的基板温度,并且在2秒或更短的时间段内基本上使药物组合物膜从基板挥发。 该装置产生含有小于约10重量%的药物组合物降解产物和所述膜的药物组合物的至少50%的气溶胶。